Iso-Eremphat 150: combined anti-tuberculosis drug
Iso-Eremphat 150 is a combined anti-tuberculosis drug produced by the German company Fatol Artsneimittel GmbH. The drug contains two active ingredients: isoniazid and rifampicin. Iso-Eremphat 150 is available in the form of film-coated tablets.
This drug is intended for the treatment of tuberculosis. It is effective in combating active forms of the disease, and can also be used to prevent tuberculosis in people who have been in contact with patients.
Like any drug, Iso-Eremphat 150 has its contraindications and side effects. It is not recommended for use in acute liver diseases, jaundice and during lactation. When using Iso-Eremphat 150, undesirable effects may occur from the central nervous system (mental disorders, convulsions, sleep disorders, memory), as well as from the gastrointestinal tract and other organs and systems of the body (neuritis, headache, impaired renal and liver function, leukopenia, anemia, allergic reactions).
The interaction of Iso-Eremphat 150 with other drugs has not been sufficiently studied, so the use of the drug in combination with other drugs should be used with caution. In case of overdose with Izo-Eremphat, 150 described cases were not recorded.
When prescribing Iso-Eremphat 150, it is necessary to take into account the characteristics of the patient, since the drug is prescribed with caution to patients with kidney disease and during pregnancy. During treatment, it is necessary to constantly monitor the functions of the liver, kidneys and organs of vision.
Thus, Iso-Eremphat 150 is an effective combined antituberculosis drug that can be used for the treatment and prevention of tuberculosis. However, when using it, it is necessary to take into account contraindications and possible side effects, as well as monitor the patient’s body functions.